Type 1 also since many users have found they can reduce their basal dose. If Afrezza became TOO successful it would end up cutting into their Toujeo and Lantus sales significantly. This is why the BEST partner is one with no other diabetes franchise at all. That gives them the incentive to go all out to push Afrezza with the specific intent of capturing maximum market share. Surely someone must be looking at the most effective insulin ever seen with just that sort of objective in mind. Marketed correctly Afrezza almost HAS to capture a serious share of the market. Best results and easiest to use should be a no-brainer with proper marketing.